Lymphomas are the most common group of hematologic malignancies. One challenge in treatment is the heterogeneous biology and the very different clinical courses of the disease. While in many cases a long-lasting disease remission or even cure can be achieved through initial treatment, some subtypes, especially relapsed and refractory (r/r) lymphomas, are still not curable and often show a very unfavorable course. At the same time, innovative therapies are available, such as targeted inhibitors of molecular signaling cascades, optimized antibodies, improved transplant regimens and cellular immunotherapies.

Against this background, a better understanding of the underlying biology, in particular the molecular pathomechanisms, is essential. The Lymphoma Study Group is therefore working on the establishment of a Bavarian registry for relapsed and refractory malignant lymphomas. A particular focus will be on the longitudinal collection of tissue samples during the course of the disease and decentralized biobanking. The aim here is - with the help of biological and reverstranslational accompanying research - to enable optimized risk and biology-adapted patient stratification as well as the development of individual treatment concepts.